NCT03396952View on ClinicalTrials.gov

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 19, 2018

Primary Completion Date

April 30, 2020

Study Completion Date

June 30, 2022

Conditions
Stage III Cutaneous MelanomaStage IIIA Cutaneous MelanomaStage IIIB Cutaneous MelanomaStage IIIC Cutaneous MelanomaStage IV Cutaneous Melanoma
Interventions
DRUG

Aspirin

Given PO

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

94143

University of Califonia, San Francisco, San Francisco

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT03396952 - Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma | Biotech Hunter | Biotech Hunter